Elisabeth Rosenthal

Whatever Happened to Biden’s Public Option?

KFF Health News Original

In the 2020 elections, then-candidate Joe Biden and many of his congressional colleagues loudly advocated for a federal “public option” health insurance plan. It was framed, at the time, as part of his incoming administration’s response to the pandemic. “Low-income Americans will be automatically enrolled in the public option at zero cost to them, though […]

This State Isn’t Waiting for Biden To Negotiate Drug Prices

KFF Health News Original

As the federal government negotiates with drugmakers to lower the price of 10 expensive drugs for Medicare patients, impatient legislators in some states are trying to go even further. Leading the pack is Colorado, where a new Prescription Drug Affordability Review Board is set to recommend an “upper payment limit” for drugs it deems unaffordable. In late […]

The No Surprises Act Comes With Some Surprises

KFF Health News Original

The No Surprises Act, the landmark law intended to protect patients from surprise out-of-network medical bills, has come with, well, some surprises. A little more than two years after it took effect, there’s good and bad news about how it’s working. First, it’s important to note that the law has successfully protected millions of patients […]

The FTC Escalates Biden’s Fight Against Drug Prices

KFF Health News Original

It’s daggers out at the Federal Trade Commission in its fight against anticompetitive practices in health care. This past year, it has issued more stringent guidelines to block and discourage hospital mergers, and it investigated practices by middlemen in the drug supply chain. Now drug manufacturers themselves are in the agency’s crosshairs. In November, the FTC challenged the validity of more […]